title: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept.
abstract: This article reports on the combined use of alefacept and etanercept in 3 patients whose psoriasis failed to respond adequately to etanercept. All patients maintained improvement for at least 8 weeks after completing 12 weeks of alefacept. No adverse events or infections were reported, and CD4+ T-cell counts remained above normal limits.
authors.affiliation: Total Skin and Beauty Dermatology Center, Birmingham, Alabama 35205, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Krell
mesh_terms: D000328:Adult; D000077944:Alefacept; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D017211:Treatment Failure
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000077944:Alefacept; D000068800:Etanercept